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ABSTRACT 
Type VI collagen is a non-fibrillar collagen expressed in many connective tissues and implicated 
in extracellular matrix (ECM) organisation. We hypothesized that type VI collagen regulates 
matrix assembly and cell function within the dermis of the skin.  In the present study we 
examined the expression pattern of type VI collagen in normal and wounded skin and 
investigated its specific function in new matrix deposition by human dermal fibroblasts.  Type 
VI collagen was expressed throughout the dermis of intact human skin, at the expanding margins 
of human keloid samples, and in the granulation tissue of newly deposited ECM in a mouse 
model of wound healing.  Generation of cell derived matrices (CDMs) by human dermal 
fibroblasts with stable knockdown of COL6A1 revealed that type VI collagen deficient matrices 
were significantly thinner and contained more aligned, thicker, and widely spaced fibres than 
CDMs produced by normal fibroblasts.  In addition, there was significantly less total collagen 
and sulfated proteoglycans present in the type VI collagen depleted matrices.  Normal fibroblasts 
cultured on de-cellularised CDMs lacking type VI collagen displayed increased cell spreading, 
migration speed, and persistence.  Taken together, these findings indicate that type VI collagen is 
a key regulator of dermal matrix assembly, composition, and fibroblast behaviour and may play 
an important role in wound healing and tissue regeneration.   
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INTRODUCTION: 
Cutaneous wound healing is a complex and dynamic set of processes that begins following injury 
and is required to re-establish skin integrity and function. Three overlapping phases of wound 
healing have been described: inflammation, tissue formation and tissue remodelling. 
Extracellular matrix (ECM) synthesis, assembly and organisation occur during the latter two 
phases and are essential for restoring tissue strength and structure (Singer and Clark, 1999). 
Dermal fibroblasts are the main cell type responsible for ECM synthesis, and dysfunctional 
matrix deposition has been implicated in both chronic, non-healing wounds and scar formation 
(Caskey et al., 2014; Herrick et al., 1992; Xue and Jackson, 2013).  Deciphering the function of 
specific regulatory molecules involved in these processes could offer new insights into impaired 
wound healing and identify therapeutic targets for wound repair and tissue regeneration. 
   
Type VI collagen is a non-fibrillar collagen that is expressed in many connective tissues and 
implicated in matrix organisation. The monomeric unit of type VI collagen is a heterotrimer 
comprised of three α chains: α1(VI), α2(VI) and α3(VI). The biosynthesis of type VI collagen 
entails intracellular assembly of the three chains into monomers, dimers and tetramers, followed 
by secretion and extracellular formation of beaded microfilaments, which are next deposited in 
the extracellular matrix (ECM) (Chu et al., 1988; von der Mark et al., 1984). Recently, three new 
chains that closely resemble α3(VI) were identified: α4(VI), α5(VI) and α6(VI) (Fitzgerald et al., 
2008; Gara et al., 2008). Unlike α3(VI) however, their distribution is limited to specific tissues 
such as skeletal muscle, myocardium and reproductive organs (Fitzgerald et al., 2013; Gara et 
al., 2011; Sabatelli et al., 2011). 
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Type VI collagen interacts with a multitude of key ECM components, including fibrillar 
collagens type I (Bonaldo et al., 1990) and II (Bidanset et al., 1992), basement membrane type 
IV collagen (Kuo et al., 1997), fibronectin (Fitch et al., 1991), glycosaminoglycans hyaluronan 
and heparin (Specks et al., 1992) and proteoglycans perlecan (Tillet et al., 1994), biglycan and 
decorin (Wiberg et al., 2001). Within connective tissue ECM, type VI collagen forms a highly 
branched filamentous meshwork which encircles the fibres of principal fibrillar collagens type I, 
II and III. In addition, in part via interactions with type IV collagen in basement membranes, it 
anchors blood vessels, nerves and mesenchymal cells (Keene et al., 1988; Kuo et al., 1997). It 
also serves as a repository for platelet-derived growth factor (Somasundaram and Schuppan, 
1996), keratinocyte growth factor (Ruehl et al., 2002), matrix metalloproteinases -1, -2, -3, -8 
and -9 (Freise et al., 2009), interleukin 2 (Somasundaram et al., 2000) and cytokine oncostatin M 
(Somasundaram et al., 2002), thus mediating their activity and availability.  
 
Mutations in any of the three genes that encode the type VI collagen chains (COL6A1, COL6A2 
and COL6A3) cause disorders affecting muscle and connective tissue, with clinical features that 
include muscular weakness and joint contractures and laxity. The two most significant diseases 
associated with type VI collagen are Ullrich congenital muscular dystrophy (UCMD) and 
Bethlem myopathy (BM) (Bushby et al., 2014). Notably, abnormal skin findings have been 
reported in many BM and UCMD patients, such as follicular hyperkeratosis, hypertrophic and 
keloid scarring, dry skin and striae rubra (Briñas et al., 2010; Collins et al., 2012; Jimenez-
Mallebrera et al., 2006; Saroja et al., 2013). Type VI collagen is expressed throughout the dermis 
of the skin and regulates hair follicle cycling (Chen et al., 2015), but its complete function within 
the tissue has yet to be determined.   
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Based on the interactions with other ECM molecules, we hypothesised that type VI collagen 
directs matrix assembly and influences dermal cell behaviour.  The present study therefore aimed 
to determine the function of type VI collagen within the dermis by analysing cell-derived 
matrices (CDMs) generated by normal and COL6A1 deficient human dermal fibroblasts.  Our 
results indicate that type VI collagen regulates both the organisation and composition of de novo 
ECM.  Importantly, these changes in the ECM have a significant impact on fibroblast 
morphology and migration.  Together, our findings provide insight into the biological function of 
type VI collagen within the skin and suggest a key role in wound healing and tissue repair.  
 
RESULTS: 
Type VI collagen expression in normal, keloid scars and acute wound healing 
Immunofluorescence detection of type VI collagen in frozen sections of human neonatal foreskin 
samples revealed that type VI collagen was widely distributed throughout the papillary dermis, 
reticular dermis and hypodermis with a higher expression in the papillary dermis (Figure 1a). A 
similar expression pattern was observed in adult skin samples with type VI collagen present 
throughout the dermis, most prominently in the papillary dermis and around the vasculature 
(Figure 1b). Keloid scarring is a pathological wound healing condition that is characterised by 
excessive matrix deposition and is thought to advance via a tongue-like expanding edge 
underneath the healthy epidermis and papillary dermis (Bran et al., 2009). Consistent with a role 
in ECM assembly, type VI collagen was highly expressed at the edges of keloid scars (Figure 
1c). This pattern was observed for all six patient samples examined, which included different 
ethnicities and scar locations (Supplementary Figure S1 and Table S1), and was distinct from the 
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pattern of type I collagen and fibronectin, which were observed more uniformly throughout the 
papillary and reticular dermis (Figure 1d,e). Type III collagen, which also has a role in matrix 
assembly (Brisson et al., 2015), localised to the papillary dermis and leading edge of keloids, 
similar to type VI collagen (Figure 1f). 
 
To determine the spatial and temporal expression pattern of type VI collagen during normal 
wound healing, full-thickness 5 mm biopsy wounds were made on the back skin of C57BL/6 
mice. Immunofluorescence staining revealed that type VI collagen was most prominently 
expressed around the wound edges (white arrows) on days 1 and 3, but not within the wound 
(Figure 1g,h). On day 7, however, type VI collagen notably increased throughout the granulation 
tissue within the re-epithelialised wound (Figure 1i). These results are consistent with previous 
findings (Chen et al., 2015) and suggest an involvement of type VI collagen in cutaneous wound 
repair, as it is deposited in the early stages of new tissue formation within the dermis. 
 
Generation of COL6A1 knockdown dermal fibroblast cell lines and cell derived matrices 
To investigate how type VI collagen regulates matrix assembly by human dermal fibroblasts, we 
developed an in vitro model of de novo matrix synthesis using the neonatal foreskin fibroblast 
cell line HCA2, immortalised with human telomerase reverse transcriptase (hTeRT) (Stephens et 
al., 2004). Quantitative RT-PCR (qPCR) analysis confirmed that these cells retain 40% COL6A1 
expression compared to primary fibroblasts, while primary keratinocytes express negligible 
levels (Figure 2a). Lentiviral transduction of three different shRNA constructs and a non-
targeting control (NTC) was utilised to develop fibroblast lines with stable knockdown of 
COL6A1. Western blot analysis demonstrated nearly complete knockdown of type VI collagen 
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for shRNA1 treatment, partial knockdown for shRNA2 and no knockdown for shRNA3 (Figure 
2b, bottom). This result was corroborated at the mRNA level with qPCR analysis, which showed 
95% knockdown for shRNA1 and 60% knockdown for shRNA2 (Figure 2b, top).  Only shRNA3 
adversely affected metabolic activity (Supplementary Figure S2). Based on these findings, 
shRNA1 (sh1) and shRNA2 (sh2) were selected for further experiments.  
 
These cell lines were subsequently employed to produce cell-derived matrices (CDMs), as 
outlined in Figure 2c. Allowing cells in long term culture to create their own ECM yields a 
naturally synthesised three dimensional and organised ECM structure that can function as a 
tissue engineering scaffold with in vivo like features (Cukierman et al., 2001; Ishikawa et al., 
1997). Immunofluorescence staining of the de-cellularised matrices confirmed the low quantity 
of type VI collagen in the sh1 CDM (Figure 2d bottom) as opposed to a type VI collagen rich 
matrix generated from NTC cells (Figure 2d top). No compensatory effects of COL6A1 
knockdown on gene expression of other type VI collagen chains (COL6A2, COL6A3, COL6A5 
and COL6A6), other collagen types, or fibronectin were detected (Supplementary Figure S3). At 
the protein level, depletion of the α1(VI) chain prevented release of α2(VI) into the media, and 
both the α2(VI) and α3(VI) chains were retained intracellularly (Supplementary Figure S4a).  We 
confirmed that this intracellular retention did not activate an unfolded protein response (UPR), as 
there were no significant changes in mRNA levels of UPR genes following COL6A1 knockdown 
(Supplementary Figure S4b) (Pan et al., 2013; Hicks et al., 2014). 
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Type VI collagen regulation of ECM structure and composition 
To determine the role of type VI collagen in de novo ECM assembly, cell derived matrices were 
produced from sh1, sh2 and NTC HCA2 cell lines. The COL6A1 knockdown cells (sh1 and sh2) 
generated matrices with more aligned fibronectin fibres as evidenced by both the representative 
immunofluorescence images (Figure 3a) and the corresponding directionality analysis (Figure 
3b), which indicates the frequency of alignment angles for the fibres. The level of alignment was 
quantified by calculating the standard deviation of the Gaussian distributions of all the 
directionality histograms, and the fibronectin fibres of sh1 and sh2 derived matrices had 
significantly narrower distributions of fibre orientations than the control matrices (Figure 3c, 
second graph). The thickness of the entire matrix was also found to be significantly greater for 
the control compared to the sh1 and sh2 matrices (Figure 3c, first graph). Finally, sh1 cells 
generated thicker fibres and had greater interfibrillar spacing compared to control and sh2 
(Figure 3c, third and fourth graphs). The intermediate changes in total matrix thickness and fibre 
alignment with the partial knockdown (sh2) indicate a dose-dependent and specific effect of 
COL6A1 knockdown on ECM organisation. Sh1 and NTC cell lines were used in all further 
experiments.  
 
To specify when the effects of type VI collagen depletion arise, fibronectin organisation was 
examined over a 10 day time-course. On day 3 the matrices appeared similar, but by day 5 the 
differences in alignment were noticeable and intensified for subsequent time points (Figure 3d). 
The above findings were validated with scanning electron microscopy (SEM) images of the 
CDMs on days 5 and 10. The control matrices were composed of a dense network of intertwined, 
mostly randomly oriented fibres, while sh1 matrices were sparser, with thicker, highly aligned 
© 2015 The Society for Investigative Dermatology
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fibres (Figure 3e). This distinctive alignment of fibronectin fibres was also exhibited by matrices 
obtained by primary fibroblasts with COL6A1 knockdown, confirming that the HCA2 model 
accurately reflects the behaviour of primary fibroblasts (Supplementary Figure S5). We therefore 
conclude that type VI collagen is required for fibroblasts to assemble a dense ECM with small 
randomly aligned fibres. 
 
To gain further understanding of how type VI collagen affects matrix composition, the CDMs 
were stained with antibodies against a panel ECM proteins (Figure 4a). Type I collagen was 
more abundant in the control matrices, which also retained their random alignment and thinner 
fibre network. Tenascin C and vitronectin were present at similar levels in both CDMs and 
appeared throughout the fibrillar network. Versican appeared in “pockets” within the CDM with 
a higher level in the NTC matrices. Finally, similar levels of decorin were observed on both 
CDMs. Biochemical assays quantitatively confirmed the immunofluorescence findings. Both 
pepsin-acid soluble, undenatured collagen measured with the Sircol™ assay and total collagen 
content measured with the Hydroxyproline assay were significantly higher for control CDMs 
compared to sh1 matrices (Figure 4b and c).  Control CDMs contained higher sulfated 
glycosaminoglycan (sGAG) content than sh1, as quantified with the DMMB assay (Figure 4d). 
The different matrices contained the same number of cells; approximately 180,000 cells (Figure 
4e). Collectively, these findings demonstrate that type VI collagen regulates the composition of 
ECM deposited by dermal fibroblasts.  
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Effect of type VI collagen on human dermal fibroblast spreading and motility 
We next interrogated how loss of type VI collagen in the ECM influenced cell behaviour. 
Primary foreskin dermal fibroblasts at passage five were seeded onto de-cellularised control and 
knockdown CDMs, and cell spreading, morphology, proliferation, differentiation, alignment and 
migration were assessed. Two dimensional fibronectin (Fn) coated glass coverslips were used as 
an additional comparison. Following twenty-four hours on the different substrates both CDMs 
promoted similar levels of cell attachment, which was significantly higher than 2D Fn (Figure 
5a,b, left). Fibroblasts on the CDMs adopted an elongated, spindle shape (Cukierman et al., 
2001) as opposed to more round and spread morphologies on the Fn control. The cell area was 
largest on the Fn control, 2704 ± 112.5 μm², followed by sh1 CDM, 2327 ± 115.7 μm², and NTC 
CDM 1901 ± 81.63 μm² (Figure 5b, middle). Interestingly, cells on the knock-down CDMs 
appeared to have more projections (Figure 5a). Finally, cell aspect ratio was significantly higher 
on both CMDs, than the Fn control (Figure 5b, right).  
 
Type VI collagen has been associated with myofibroblast differentiation (Naugle et al., 2006) 
and is expressed by adipocytes (Pasarica et al., 2009). After 7 days of culture, almost all of the 
fibroblasts were α-smooth muscle actin (aSMA) positive on the CDMs and less so on the Fn 
control (Figure 5c and 5d, left). The percentage of Ki67 positive cells was also higher on the 
CDMs than the Fn control (Figure 5c and 5d right). Oil red O staining of the cultured cells 
revealed complete absence of adipogenic differentiation for all three conditions (Figure 5e).  
 
We then co-stained for phalloidin and fibronectin to visualise the cells in relation to the CDMs.  
Cells on the type VI collagen depleted CDMs were oriented parallel with the Fn fibres, in 
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contrast with a more random orientation for cells on the control CDMs (Figure 6a). We also 
explored the role of type VI collagen in fibroblast migration by time-lapse microscopy on the 
three different substrates. The cells displayed distinct migratory behaviours: they travelled the 
most distance on the sh1 CDMs compared to the NTC and Fn control, as illustrated by the 
representative cell track plots (Figure 6b) and the migration movies (Supplementary Movie M1). 
Cells on the sh1 CDMs migrated with the greatest speed, followed by cells on the control CDMs 
and then 2D Fn (Figure 6c, left). Cells on sh1 CDMs also exhibited slightly higher persistence 
compared to NTC CDMs and Fn control (Figure 6c, right). Taken together, these results indicate 
that type VI collagen influences fibroblast spreading, alignment and motility but has no effect on 
proliferation or differentiation.                 
 
The effects of type VI collagen depletion on cell migration could also be observed between NTC 
CDMs from day 7 and sh1 CDMs from day 10, at which point the thickness of both matrices is 
approximately 8 μm, and cells migrated similarly on 2D surfaces coated with purified type VI 
collagen and fibronectin compared to fibronectin alone (Supplementary Figure S6). Consistent 
with previous reports in which topographical cues from the ECM direct cell migration (Kutys et 
al., 2013), we also find that dermal fibroblasts migrate along fibronectin coated aligned 
polystyrene fibres generated by electrospinning (Supplementary Movie S2). These results 
therefore suggest that type VI collagen-dependent changes in matrix structure, rather than 
composition, regulate fibroblast motility. 
© 2015 The Society for Investigative Dermatology
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DISCUSSION: 
 
The overall aim of this study was to investigate the role of type VI collagen in the assembly of 
ECM by human dermal fibroblasts and evaluate the subsequent impact on cell behaviour.  By 
characterising CDMs generated by COL6A1 knockdown and control fibroblasts we demonstrate 
that type VI collagen mediates ECM architecture and composition and affects fibroblast 
morphology and migration.  In conjunction with the presence of type VI collagen throughout the 
dermis of intact skin and within the newly formed granulation tissue of acute wounds, these 
results suggest that it may play an important role in wound repair.  Thus, our findings provide 
insight into the function of type VI collagen within the skin. 
 
In agreement with our studies, Sabatelli et al. observed abnormal fibronectin deposition in the 
ECM from fibroblasts of a Bethlem myopathy patient and also from Col6a1 null mice (Sabatelli 
et al., 2001). Type VI collagen has also been shown to modulate type I collagen fibrillogenesis  
(Minamitani et al., 2004), and type I collagen fibrils appear irregular in UCMD patients' skin 
(Kirschner et al., 2005).  Consistent with our results in the mouse, type VI collagen is deposited 
during the early stages of wound healing in human skin, and its synthesis increases in parallel 
with type I collagen, reaching a peak approximately 8 days post-wounding (Betz et al., 1993; 
Oono et al., 1993). Although Lettmann and colleagues recently described no effects of type VI 
collagen deficiency on overall wound closure time, both the tensile strength and collagen fibril 
architecture were disrupted in the skin of Col6a1 null mice (Lettmann et al., 2014).  
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Interestingly, we find that type VI collagen is highly expressed at the expanding margins of 
keloid scars, not only for Afro-American ear-lobe samples (Peltonen et al., 1991), but also for 
additional ethnic groups and anatomical sites including abdomen and occipital scalp.  Given its 
role in matrix assembly, type VI collagen may therefore contribute to excess matrix deposition 
and the pathogenesis of keloid scar formation.  
 
The most striking effect of loss of type VI collagen in the present study was on fibroblast 
motility. Cells migrated with increased speed and persistence on the highly aligned CDMs 
lacking type VI collagen. Topography of the fibrillar network likely directs migration; a more 
aligned matrix provides guidance cues for rapid and directionally persistent cell movement 
(Kutys et al., 2013). Furthermore, the increased spreading of fibroblasts on the knockdown 
CDMs could potentially be attributed to the increased interfibrillar spaces.  Significantly, these 
results demonstrate how type VI collagen dependent changes in the ECM directly impact dermal 
cell behaviour. 
 
While it is clear that type VI collagen plays an key role in regulating dermal tissue architecture 
and fibroblast function, several important questions remain.  For example, it is unclear which 
specific subdomains within the protein interact with other ECM components to control 
fibrillogenesis.  We speculate that as a microfibrillar collagen that physically interacts with 
fibrillar ECM components (e.g. fibronectin and collagen I), type VI collagen alters 
fibrillogenesis by displacing other ECM components, leading to fibril branching and a more 
randomly oriented matrix.  In addition to understanding the molecular mechanisms by which 
type VI collagen controls matrix assembly, it will also be interesting in future studies to explore 
© 2015 The Society for Investigative Dermatology
 14 
its role in ageing and other skin pathologies, such as chronic wounds.  Finally, type VI collagen 
could be a potential therapeutic target for tissue repair.  Delivery of exogenous type VI collagen 
may be advantageous for stimulating matrix deposition, while inhibiting its expression may be 
desirable for reducing fibrosis and scar formation.  Thus, tuning the levels of type VI collagen 
within the tissue could represent an approach to modulating tissue regeneration. 
 
MATERIALS AND METHODS: 
Human tissue samples 
Skin samples were obtained from keloid patients and healthy volunteers from the plastic surgery 
department at Barts Health NHS Trust. Foreskin samples were obtained from neonatal 
circumcision procedures. All subjects gave written, informed consent and the study was 
conducted under local ethical committee approval (East London Research Ethics Committee, 
study no 2011-000626-29) and according to the Declaration of Helsinki. Details of patient skin 
are listed in Supplementary Information Table S1.  
 
Cell culture 
Primary dermal fibroblasts and HCA2 cell lines were cultured in Dulbecco’s Modified Eagle’s 
Medium (DMEM) containing GlutaMAX™ (Gibco, Invitrogen, Paisley, UK), 10% fetal bovine 
serum (FBS) (labtech.com, Uckfield, UK) and 1% penicillin and streptomycin (Gibco, 
Invitrogen) at 37°C in a humidified atmosphere of 5% CO2/95% air. The culture medium was 
changed every two to three days and the cells were passaged at 70 to 80% confluency.   
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CDMs were generated as previously described with minor modifications (Beacham et al., 2007). 
Briefly, sterile 13 mm glass coverslips were incubated with 0.2% sterile gelatin for 60 min at 
37°C (gelatin type B, Sigma). They were washed 3 times with PBS, cross-linked with 1% sterile 
glutaraldehyde for 30 min at room temperature (RT) and again washed 3 times with PBS. Cross-
linking was quenched with 1M sterile glycine in PBS for 20 min at RT, followed by 3 times PBS 
washing and incubation in growth medium (DMEM, 10% FBS, 1% P/S) for 30 min at 37°C and 
finally 3 times PBS washing. The coverslips were either used immediately or stored at 4°C for a 
maximum of 4 weeks.  Dermal fibroblasts were plated at a density of 60,000 cells per well and 
cultured overnight in 37°C, 5% CO2 to achieve full confluency. Medium supplemented with 50 
μg/ml ascorbic acid was added and subsequently changed every two days. Cells were cultured 
for 10 days. 
 
To denude cells, medium was aspirated and cells were washed once with PBS. Pre-warmed 
extraction buffer was then added (10mM NH4OH, 0.25% Triton X-100 in PBS) and left for 4 
min to allow cell lysis. Half of the buffer was carefully removed and PBS was added (Gibco, 
Invitrogen). The same step was repeated until no intact cells were visible. The DNA residue was 
digested with 10 μg/ml DNase I (Roche) in PBS for 30 min at 37°C, 5% CO2, followed by two 
washes with PBS. Matrices were stored at 4°C in PBS with pen/strep for up to 4 weeks. 
 
See Supplementary Information for additional materials and methods. 
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FIGURE CAPTIONS 
 
Figure 1: Type VI collagen expression in normal and wounded skin. (a) Representative 
image of type VI collagen localisation (red) in frozen sections of neonatal foreskin. (b-c) 
Representative images of type VI collagen localisation (red) in paraffin embedded sections of (b) 
adult abdominal skin or (c) abdominal keloid scars. Samples were co-stained for keratin 14 or 
CD31 (green) to demarcate the epidermis or blood vessels, respectively.  Keloid sections were 
also stained for type I collagen (d) type III collagen (e), and fibronectin (f).  Arrows indicate the 
scar edge. (g-i) Immunofluorescence images of type VI collagen (red) and keratin 14 (green) in 
frozen sections of wounded mouse skin at days (g) 1, (h) 3, and (i) 7 post-wounding.   Excisional 
wounds were made on the back skin of 6-8 week old, male C57Bl/6 mice using a 5 mm biopsy 
punch.  Arrows denote wound margins. F=fibrin clot, GT=granulation tissue, NE= neo-
epidermis. Scale bars: 100 μm. Insets are 2X zoom. 
 
Figure 2: shRNA mediated knockdown of COL6A1 in dermal fibroblasts. (a) Quantification 
of COL6A1 expression in cultured primary human dermal fibroblasts, HCA2 fibroblasts, and 
primary human keratinocytes by qRT-PCR.  Expression was normalised to GAPDH and 
expressed relative to primary fibroblasts. (b) QRT-PCR analysis of COL6A1 expression in 
HCA2 cells transduced with COL6A1 shRNA constructs (sh1 and sh2) or non-targeting control 
(NTC) constructs, normalised to GAPDH and expressed relative to NTC.  Western blot analysis 
of type VI collagen expression in cells transduced with COL6A1 shRNA constructs (sh1, sh2, 
and sh3), transduced with NTC constructs, or untreated (UTC).  (c) Schematic of procedure for 
generation of cell-derived matrices (CDMs). (d) Representative immunofluorescence images of 
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type VI collagen deposition in CDMs generated by NTC and sh1 expressing cells after 10 days 
in culture. Data represent mean ± S.E.M. (N=6). Scale bars: 25 μm 
 
Figure 3: Type VI collagen mediates ECM assembly. (a) Representative immunofluorescence 
images of fibronectin (Fn) fibres of CDMs generated by HCA2 cells expressing NTC, sh1, or 
sh2 shRNA after 10 days in culture.  (b) Corresponding histograms of fibre orientation 
distribution for representative images in panel a. (c) Quantification of total CDM thickness, 
Gaussian standard deviation of fibre orientation, interfibrillar space and fibre diameter for CDMs 
produced by NTC, sh1, or sh2 expressing cells. Data represent mean ± S.E.M. (N=3 
experiments, 15 images per experiment) *p<0.05 and ***p<0.001 versus NTC, ###p<0.001 
versus sh2.  (d) Representative images of Fn fibres produced by NTC or sh1 expressing cells at 
days 3, 5, 7, and 10.  (e) SEM images of CDMs at days 5 and 10. Scale bars: 25 μm for a and d 
and 10 μm for e.   
 
Figure 4: Type VI collagen affects ECM composition. (a) Representative immunofluorescence 
images of type I collagen, vitronectin, tenascin C, versican, and decorin in CDMs generated by 
NTC and sh1 expressing cells.  (b-e) Quantification of biochemical composition of CDMs, 
including (b) soluble collagen using the Sircol™ assay, (c) total collagen using the 
hydroxyproline assay, (d) DNA content using the Hoechst dye assay, and (e) sGAG content 
using the DMMB assay.  Data represent mean ± S.E.M. (N=3 experiments) *p<0.05.  Scale bars: 
25 μm.     
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Figure 5: Dermal fibroblast morphology is altered on collagen VI depleted CMDs. (a) 
Fluorescence images of F-actin (green) in primary dermal fibroblasts cultured for 24 hours on 
CDMs derived from NTC or sh1 expressing cells or on Fn coated coverslips.  (b) Quantification 
of fibroblast number, spread area, and aspect ratio on CDMs or Fn coated surfaces. (c) 
Immunofluorescence images of α-smooth muscle actin (aSMA, red) and Ki67 (green) expression 
in primary dermal fibroblasts cultured on CDMs derived from NTC or sh1 expressing cells or Fn 
coated coverslips for 7 days (no ascorbic acid in medium). (d) Quantification of aSMA and Ki67 
positive cells on CDMs and Fn coated coverslips after 7 days.  (e) Representive images of 
primary fibroblasts stained with oil red O and counterstained with haematoxylin following 7 
days of culture on CDMs or Fn surfaces.  All data represent mean ± S.E.M. (N=3 experiments), 
*p<0.05, **p<0.01 and ***p<0.001 versus NTC, #p<0.05, ##p<0.01 and ###p<0.001 versus 
sh1. Scale bars: 25 μm. 
 
Figure 6: Type VI collagen depleted CDMs enhance fibroblast motility. (a) 
Immunofluorescence images of primary fibroblast morphology (F-actin, green) in relation to Fn 
fibres (red) of CDMs generated by NTC or sh1 expressing cells. (b) Tracks of individual cells 
migrating on CDMs or Fn coated tissue culture wells. Cells were imaged using time-lapse phase-
contrast microscopy and analysed with ImageJ. (c) Quantification of single cell velocity and 
persistence (directionality) on CDMs or Fn coated tissue culture wells. Data represent mean ± 
S.E.M.  (N=4 experiments), *p<0.05 and ***p<0.001 versus NTC, ###p<0.001 versus sh1. Scale 
bars: 25 μm.   
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